Leto Laboratories, a company on new drug (protein-based drug) development, completed Series B financing of over $15 million for clinical development of cytokine drugs
Leto Laboratories Co., Ltd. (“Leto Laboratories”) today announced it has completed a $15+ million Series B funding round, invested by Yijing Capital, Qiaojing Capital, and Beijing Changping Science Park Development. Instant Capital was the exclusive financial advisor.
Published: October 16, 2020
$150 Million- TopAlliance Obtains a Global License for an IL-2 Drug from Leto Laboratories
TopAlliance announced a recent agreement with Leto Laboratories, the “Technology License Contract for an IL-2 Drug with Unique Intramolecular Disulfide Bonds”, on August 28th. TopAlliance is exclusively licensed for the preclinical development, clinical research, and commercialization of this IL-2 drug (Code Name: LTC002) and for the use of related patented technology worldwide. The prepayment, milestone payments, and technical service fees of this transaction amount to over $150 million (959 million RMB).
Published: August 29, 2021
Biotech company Leto Laboratories raises tens of millions of RMB in Series A funding round
Biotech company Leto Laboratories raises tens of millions of RMB in Series A funding round, led by Med-Fine Capital and co-invested by Hygeia Capital, Qirong Venture Capital, and its existing investor SHERPA Healthcare Partners.
Published: March 19, 2019
No more data……